Background: Identifying risk factors for breast cancer specific to women in their 40s could inform screening decisions.
C
urrent practice guidelines on mammography screening differ in their recommendations for women in their 40s (1) (2) (3) . The U.S. Preventive Services Task Force recommends individualized, informed decision making about when to start mammography screening based on a woman's values about benefits and harms (4) . Risk-based screening has been recommended for other health conditions in the United States and may provide a similar evidence-based approach for breast cancer. However, applying this approach to clinical practice has been problematic because it is unclear how women and clinicians can effectively consider individualized risk factor information in their discussions of benefits and harms.
Microsimulation models of mammography screening developed as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) indicated that women with approximately 2-fold increased risk for breast cancer who started biennial screening at age 40 years had similar benefits (life-years gained) and harms (false-positive results) as average-risk women who started screening at age 50 years (5) . The risk threshold was higher when the CISNET models considered reduction in breast cancer deaths as a benefit (risk ratio [RR], 3.3) or annual rather than biennial screening (RR, 4.3). These results suggest that identifying women with at least a 2-fold increased risk for breast cancer could be useful in determining whether to initiate mammography screening before age 50 years.
Much research has been published describing personal and clinical risk factors associated with breast cancer. However, studies generally included women of various ages, measured and reported risk factors in different ways, and provided wide ranges of risk estimates. Consequently, results of broad-based epidemiologic studies may not be clinically applicable to the screening decisions of individual women and in some cases may be misleading.
The purpose of this systematic review and metaanalysis is to determine what factors increase risk for invasive breast cancer, specifically for women aged 40 to 49 years, and to estimate the magnitude of risk for each factor compared with average-risk women. It focuses on women who are eligible for screening mammography under current practice guidelines in the United States and considers average-risk women to be those without the risk factor or who represent the mean or majority of women in the cohort, depending on the risk factor. This project was conducted in collaboration with development of the CISNET models of mammography screening based on increasing levels of risk and builds on previous work (6, 7) .
METHODS Data Sources and Searches
A standard protocol was developed and followed for this review. In conjunction with a research librarian, we used the National Library of Medicine's Medical Subject Headings keyword nomenclature to search MEDLINE (1996 to the second week of November 2011), the Cochrane Central Register of Controlled Trials (fourth quarter of 2011), and the Cochrane Database of Systematic Reviews (fourth quarter of 2011) for relevant Englishlanguage studies and systematic reviews. We also conducted secondary referencing by manually reviewing reference lists of papers and by using Scopus to search citations of key studies. Searches included studies published during the past 16 years to provide data that are relevant to current cohorts of women considering mammography screening and to correspond to the time frame of risk factor data collected by the Breast Cancer Surveillance Consortium (BCSC) that were also used in this study.
Study Selection
We developed inclusion and exclusion criteria for abstracts and articles based on the target population, risk factors, and outcome measures. We included randomized, controlled trials; observational studies; systematic reviews; and meta-analyses. After an initial review of abstracts, we retrieved full-text articles and conducted a second review by using additional inclusion criteria defined specifically for each risk factor, including eligibility of the data for statistical meta-analysis. When sufficient studies were not available for a meta-analysis, we used the best evidence as determined by consensus among the investigators on the basis of study quality, size, and applicability.
The target population consisted of women aged 40 to 49 years who were eligible for screening mammography. Studies were excluded if they enrolled women who were not candidates for routine screening because they had prior breast or ovarian cancer, ductal carcinoma in situ or other noninvasive breast cancer, current breast physical findings, presence of deleterious BRCA1/BRCA2 mutations in self or relatives, or prior chest radiation for such conditions as lymphoma. Included studies were conducted in countries with patient populations and health care services similar to those of the United States to ensure applicability. Studies that reported outcomes in age groups that differed from the 40-to 49-year age category were included if most participants were aged 40 to 49 years and all were younger than 55 years. When studies reported outcomes by menopausal status rather than age, we used results for premenopausal women as long as the group included a majority of women in their 40s.
The main outcome measure was incidence of invasive breast cancer at age 40 to 49 years or invasive and noninvasive breast cancer as a combined outcome when this was the only measure reported in a study.
Risk factors included race and ethnicity, body mass index (BMI), physical activity, alcohol use, smoking, family history of breast cancer, breast density, prior breast procedures, and reproductive factors (age at menarche; parity; age at birth of first child; breastfeeding; oral contraceptive use; menopausal age, status, and type; and menopausal hormone therapy). We included studies meeting the following criteria: studies of risk factors for recent or current status that reflected exposure within 1 year of breast cancer diagnosis; studies of physical activity that reported categories of exercise descriptively (inactive, some, or regular) or quantified by metabolic equivalents; studies of alcohol use and smoking that reported use status (current, former, or never), recency, and amounts of use (drinks per week or packs per day); and studies of oral contraceptive and menopausal hormone therapy use that investigated any formulation (combination, progestin, or estrogen only) and used various definitions of ever and never use. We excluded studies of nonoral forms of contraception and those evaluating formulations not applicable to the target population (8) .
We included studies that defined parity as the number of full-term births, full-term pregnancies, live births, or pregnancies lasting 6 months or more regardless of outcome, consistent with standard medical definitions (9) . We included studies of breastfeeding that used a nonbreastfeeding group of parous women as the reference category and determined breastfeeding activity (ever or never) and total duration.
We included studies that reported menopausal status and history of hysterectomy or oophorectomy if the event preceded the breast cancer diagnosis in women in their 40s. We reviewed studies of mammographic breast density that used several methods to categorize density, but we reported results only from studies that used the Breast Imaging Reporting and Data System (BI-RADS) classification (1 ϭ almost entirely fat, 2 ϭ scattered fibroglandular densities, 3 ϭ heterogeneously dense, and 4 ϭ extremely dense) because of its clinical relevance to practice in the United States (10).
Data Extraction and Quality Assessment
For the included studies, an investigator abstracted the following data: study design, setting, participant characteristics (including age, race and ethnicity, and diagnosis), enrollment criteria, exposures (dose and duration), procedures for data collection, number enrolled and number lost to follow-up, methods of exposure and outcome ascertainment, analytic methods (including adjustment for confounders), and results for each outcome. A second investigator confirmed the accuracy of key data.
We used predefined criteria developed by the U.S. Preventive Services Task Force to assess the quality of studies (11) . Two investigators independently rated the quality of each eligible study (good, fair, or poor), and final ratings were determined by consensus among raters. We used only studies rated as good or fair to determine risk estimates.
We assessed applicability of studies by using the PICOTS (population, intervention, comparator, outcomes, timing of outcomes measurement, and setting) approach (12) . In addition, applicability of case-control studies was based on the control group population. For all studies, applicability was high if participants were recruited predominantly from community populations rather than clinical populations. For each risk factor, we also determined the consistency of results (that is, the degree of similarity in the effect sizes of the different studies). Studies were considered consistent if outcomes were generally in the same direction of effect and ranges of effect sizes were narrow. Applicability and consistency were determined by consensus of the investigators who reviewed the studies and conducted the meta-analyses.
Data Synthesis and Analysis
For eligible studies, we combined data in several metaanalyses to obtain more precise estimates of the relationship between risk factors and breast cancer. All included studies had cohort or case-control designs, and only studies reporting estimates that adjusted for at least 1 potential confounder in their analysis were included in the meta-analysis. To determine the appropriateness of metaanalysis, we considered clinical and methodological diversity and assessed statistical heterogeneity.
We abstracted or calculated estimates of RRs (odds ratio, rate ratio, or hazard ratio) and their SEs from each study and used them as the effect measures. Because the incidence of breast cancer was low, we considered the estimates of odds ratios to be equivalent to estimates of relative risks (rate ratio or hazard ratio). This assumed that the underlying event rates in the case-control studies, for example, reflected the low incidence rate in the population.
For most risk factors, studies reported RRs based on similar cut points across included studies and we used estimates based on the reported cut points. For BMI, the cut points were too disparate to be combined as reported in the published studies. Therefore, we combined BMI categories to correspond to the World Health Organization definitions of underweight (Ͻ18.5 kg/m 2 ), normal weight (18.5 to Ͻ25 kg/m 2 ), overweight (25 to Ͻ30 kg/m 2 ), and obese (Ն30 kg/m 2 ) (13). We combined the underweight and normal weight categories because too few women were included in the underweight group. When studies categorized BMI by using other cut points, we calculated RRs by assuming that BMI is log-normally distributed and that a linear association exists between breast cancer risk and BMI on the logit scale. We estimated distribution parameters of BMI from published information in each study.
We assessed the presence of statistical heterogeneity among the studies by using standard chi-square tests and the magnitude of heterogeneity by using the I 2 statistic (14) . We used a random-effects model to account for variation among studies. In general, when there is no variation among studies, the random-effects model yields the same results as a fixed-effects model without a study effect (15) . To explore heterogeneity, we used meta-regression to assess the effect of the degree of adjustment for confounders in the original studies. This was quantified by the total number of adjusted variables and the number of adjusted risk factors considered in the review as well as other studylevel variables, such as quality, study design, and breast cancer type. We also conducted sensitivity analyses to assess the robustness of results that considered variation from different definitions of risk factors and reference groups, inclusion of noninvasive breast cancer as an outcome, and outlying studies. The results of the sensitivity analyses indicated no major differences from the main analysis.
For specific risk factors (BMI, age at menarche, and age at birth of first child), we recalculated RRs from the meta-analysis by using reference groups that differed from the original studies to approximate average risk in the population. The new reference groups were chosen to align with the distribution or mean of risk factors in the target population to provide more clinically relevant risk estimates. Data describing distributions or means in the target population were obtained from various sources representing U.S. national samples (16 -22) (Appendix Table, available at www.annals.org).
Comparison With BCSC Data
We included data from the BCSC to supplement the systematic review because some risk factors were not reported in published studies. The BCSC is a national collaboration of 5 mammography registries and 2 affiliate sites in the United States that prospectively collects data on breast imaging, risk factors, and breast cancer outcomes (23) . We analyzed BCSC data collected from 1994 to 2010 for women aged 40 to 49 years at the time of screening mammography. Risk factor data were obtained at the time of each screening mammography and reported in categories similar to those defined by the systematic review. Results for 380 585 women aged 40 to 49 years were provided in proportional hazards models adjusted for age, race, family history of breast cancer, and BMI and stratified by site. We used partly conditional Cox regression (24) to incorporate multiple observations per woman (allowing her to enter the analysis at each eligible screening mammography) and accounted for multiple observations per woman by using the robust sandwich estimator of the SE (25). Women were followed until they were diagnosed with invasive breast cancer; until they were censored at the first occurrence of ductal carcinoma in situ, death, age 50 years, or end of complete cancer follow-up or eligibility for her site; or for 5 years after the examination date. Mean length of follow-up was 3.3 years.
All analyses for the meta-analysis and BCSC data were performed by using Stata, version 11.0 (StataCorp, College Station, Texas), and were reported as RRs with 95% CIs.
Role of the Funding Source
The National Cancer Institute funded this work but had no additional role in the design, conduct, or reporting of the review and analysis.
RESULTS
A total of 9036 abstracts were identified by search criteria; of these, 884 full-text articles were reviewed and 95 met the inclusion criteria as well as the criteria for good or fair quality (Figure) . Sixty-one studies of 8 risk factors (BMI, alcohol use, smoking, age at menarche, parity, age at first birth, breastfeeding, and oral contraceptive use) provided data for meta-analysis. Two published meta-analyses of family history of breast cancer reported results specifi- BMI ϭ body mass index; OC ϭ oral contraceptive. * Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews. † Reference lists, Scopus, and studies suggested by experts. ‡ Some articles are included for more than 1 risk factor. § Published meta-analyses. || No articles met inclusion criteria for race and ethnicity, menopausal stage and type (surgical or nonsurgical), age at menopause, and menopausal hormone use. ¶ Although some studies met inclusion criteria for the systematic review, they did not provide data for the meta-analysis because they used dissimilar categories or different measures from the other included studies.
cally for women in their 40s (26, 27) . Single studies provided estimates for 3 risk factors because either they were the only studies that met the inclusion and quality criteria for the risk factor (prior breast procedure) or studies did not provide data that could be used in a meta-analysis (breast density and physical activity). Individual studies providing data for risk estimates are described in the Supplement (available at www.annals.org). Data from the BCSC provided the only estimates for 3 risk factors that had no published studies that met the inclusion criteria (race and ethnicity, menopausal status and type, and menopausal hormone therapy). No data were available to evaluate age at menopause.
Personal Risk Factors
Personal risk factors included race and ethnicity, BMI, physical activity, alcohol use, and smoking ( Table 1) . Data from the BCSC indicated no statistically significant increased risks for breast cancer by race and ethnicity when white race was used as the reference group.
For BMI, a meta-analysis of 18 studies (17, 28 - Ten studies of physical activity met inclusion criteria (45-54) but could not be combined in the meta-analysis because they used different measures of activity and reported results in dissimilar categories. All studies reported no statistically significant differences in breast cancer risk based on physical activity. Results from a large, goodquality study designed to specifically assess the relationship between physical activity and premenopausal breast cancer provided the estimates in Table 1 (46) . Data on physical activity were not available from the BCSC.
Although 12 studies reporting various measures of alcohol use met inclusion criteria (31, 36, (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) , results from only 3 studies could be combined in the metaanalysis (55, 61, 64) . Using no alcohol use as the reference group, results indicated higher risk estimates with increasing amounts of alcohol consumption; however, all CIs included 1.0. Smoking use (never vs. ever) and status (never vs. current or former) had no significant associations with breast cancer based on meta-analyses of 12 studies of never versus ever use (31, 62, (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) and 7 studies of never versus current or former use (31, 62, 67, 70 -73) . No BCSC data on alcohol use or smoking were available.
Family History, Breast Density, and Breast Procedures
In an analysis of data from 52 epidemiologic studies (26) Table 2) . Data from the BCSC also showed higher risk for women with a first-degree relative with breast cancer (RR, 1.86 [CI, 1.69 to 2.06]). In both the meta-analysis and the BCSC results, risk was higher among women with first-degree relatives who were diagnosed at younger ages than those diagnosed at older ages. Risk ratios for women with relatives younger than 40 years compared with women with no first-degree relatives were 3.0 (CI, 1.8 to 4.9) in the meta-analysis (26) and 2.17 (CI, 1.86 to 2.53) for women with relatives younger than 50 years in the BCSC. Risk was lower for women with relatives diagnosed at age 60 years or older (RR, 1.7 [CI, 1.3 to 2.1]) (26) . In a meta-analysis of 2 studies (27), risk was also significantly increased for women with 1 or more second-degree relatives compared with none (RR, 1.7 [CI, 1.4 to 2.0]).
A published study of BCSC data reported risk estimates for breast cancer by using BI-RADS breast density categories and defined BI-RADS category 2 (scattered fibroglandular densities) as the reference group (75 Twelve studies of oral contraceptive use provided estimates for the meta-analysis of ever use compared with never use (31, 74, 77, 78, (97) (98) (99) (100) (101) (102) (103) (104) , and 8 studies provided estimates for recency of use, with the most recent category defined as within 5 years (77, 78, 99 -104) . None of these associations was statistically significant, although all point estimates were increased ( Table 3) . Data from the BCSC indicated significantly higher risk for breast cancer for current oral contraceptive use than for former or never use (RR, 1.30 [CI, 1.13 to 1.49]).
Data from the BCSC showed reduced breast cancer risk for perimenopausal and postmenopausal women (either surgical or nonsurgical menopause) compared with premenopausal women. The BCSC data also indicated that women with no uterus currently using menopausal hormone therapy had a reduced risk for breast cancer compared with nonusers (RR, 0.70 [CI, 0.52 to 0.94]), whereas those with a uterus had no significant association. Presumably, women without a uterus were using estrogen alone, whereas those with a uterus were using estrogen combined with progestin.
DISCUSSION
Sixty-six studies identified in the systematic review contributed data for breast cancer risk estimates for 13 unique risk factors, whereas data from the BCSC provided estimates for 11 risk factors, 3 of which were not included in published studies. Both sources provided estimates for some risk factors that were expressed in alternate ways, such as in dichotomous as well as ordinal categories. A summary of evidence for the systematic review describes the number and design of included studies; breast cancer outcomes; and ratings for quality, consistency, and applicability for each risk factor (Table 4) . Overall, studies were consistent and applicability was high, largely because conditions of the study population were incorporated into inclusion criteria.
Results indicated that women in their 40s with extremely dense breasts on mammography or at least 1 first-degree relative with breast cancer had at least a 2-fold increased risk for breast cancer ( Table 5 ). This level of risk corresponds to the risk threshold of the CISNET models, which demonstrated similar benefits and harms for increased-risk women starting biennial screening at age 40 years and average-risk women starting at age 50 years (5). Risk was even higher among women with 2 or more first-degree relatives with breast cancer or first-degree relatives diagnosed before age 40 years.
The following 3 factors were associated with a 1.5-to 2.0-fold increased risk: a prior benign breast biopsy result, a second-degree relative with breast cancer, and heterogeneously dense breast tissue. Current use of oral contraceptives, nulliparity, and first birth at age 30 years or older were associated with a 1.0-to 1.5-fold increased risk, although some results differed by data sources, which suggests inconsistency. Several factors were associated with lower-than-average risk, including BMI of 25 kg/m 2 or higher; low breast density; age 15 years or older at menarche; birth of 3 or more children; breastfeeding; perimenopausal or postmenopausal status; and use of menopausal, estrogen-only hormone therapy.
Although the results of this review are consistent with previous research, our estimates of risk are unique and relevant to current clinical dilemmas about mammography screening for women in their 40s. Although most women who develop breast cancer have no known risk factors, information about risk may be particularly useful when making decisions about screening. Of note, several risk factors identified in single studies or in studies of women of various ages were not statistically significant in our analysis. These findings may be useful to women, clinicians, and health systems considering risk-based screening who find a long list of potential risk factors difficult to navigate. Focusing on high breast density and first-degree family history of breast cancer may be a more clinically feasible approach to personalized screening. BCSC ϭ Breast Cancer Surveillance Consortium; NA ϭ not available. * Model included age, race, body mass index, family history of breast cancer, and site. Numbers of women included in estimates varied by risk factor because of missing data. † Among women who gave birth. ‡ Bilateral oophorectomy. § Usually hysterectomy without bilateral oophorectomy. Assumed women without a uterus were using estrogen only and women with a uterus were using estrogen combined with progestin.
Family history is an important, well-established risk factor for breast cancer, and its role in breast cancer screening and prevention extends beyond mammography. Current recommendations from the U.S. Preventive Services Task Force for women with family histories of breast cancer include genetic counseling and mutation testing if appropriate (105) and consideration of medications to reduce risk for primary breast cancer (106). * Consistency refers to the degree of similarity in the effect sizes of different studies within an evidence base. Studies were consistent if outcomes were generally in the same direction of effect and ranges of effect sizes were narrow. † Applicability of case-control studies was based on the control group population. For all studies, applicability was high if participants were recruited predominantly from community populations rather than clinical populations.
Several studies have reported associations between mammographic breast density and breast cancer (107) (108) (109) (110) (111) , but only 1 met inclusion criteria for this review because it reported results with BI-RADS classifications that are used in U.S. clinical practice and provided risk estimates specific to the target population (75) . The use of breast density in screening and prevention is currently unclear, although research suggests that it may be important for estimating risk (111) (112) (113) (114) and for determining the age at which screening should begin and appropriate screening intervals (115) . However, clinical trials of these strategies have not been done and use of breast density in current practice poses such challenges as variability of reporting among radiologists (116).
Our risk estimates were derived from epidemiologic data, and their application in predicting individual risk has not been evaluated. They may be particularly useful for developing more complex risk prediction models. Although several such models exist (for example, the Gail model), they were not developed specifically for women in their 40s, were not based on recent research, and have low discriminatory accuracy in predicting individual risk (117). Improving risk models and demonstrating their effectiveness in clinical applications are necessary future steps in this work.
Although our risk estimates may be useful in informing clinical practice, effective methods to modify risk factors to reduce breast cancer incidence are largely untested. Our results indicated reduced breast cancer risk for women with BMIs in the overweight and obese categories. However, an inverse association has been found in postmenopausal women (118). Given the higher incidence of breast cancer in postmenopausal women, an appropriate clinical recommendation would be to modify weight gain after menopause rather than at a younger age. Some risk factors may reflect underlying biological effects that cannot be modified for disease prevention purposes, such as parity. In contrast, breast density was reduced in high-risk women receiving tamoxifen in clinical trials (119) . How to apply this information to individual patients is currently unclear.
This evidence review and meta-analysis is limited in several ways. Studies reported different measures, dissimilar categories for exposures and outcomes, and reference groups that did not represent average risk in the target population. Studies also varied in the degree of adjustment for confounders in their risk estimates. All of these variations could lead to potential bias in the combined estimates of RRs. In addition, some women outside the targeted age group were included because studies provided data in categories that did not align with ours. Publication bias and selective reporting are also potential limitations but are difficult to assess.
To address these issues, we developed inclusion criteria that considered the quality and applicability of studies consistently across risk factors, included only fair-or goodquality studies, selected best-evidence estimates for risk factors that lacked estimates from a meta-analysis, and redefined reference groups to approximate the mean or distribution of the target population. In addition, we analyzed primary BCSC data to supplement or support the metaanalysis results. To address concerns of heterogeneity, we performed several sensitivity analyses, including an analysis BCSC ϭ Breast Cancer Surveillance Consortium; BI-RADS ϭ Breast Imaging Reporting and Data System. * BCSC estimates from published analyses; similar BCSC estimates calculated from primary data are provided in Table 2 . † Nulliparity was calculated in 2 ways ( Table 3) . Estimates indicating significantly increased risk for nonparous compared with parous women were similar for the meta-analysis and the BCSC data. Estimates comparing ages at first birth that included nonparous women provided significant results for the meta-analysis only. ‡ Results were not statistically significant for the BCSC data.
based on the degree of adjustment for confounders, and we found no important differences in results. Data in the meta-analysis and the BCSC were derived from observational studies that were subject to inherent potential biases, such as unmeasured and uncontrolled confounders. Our analysis was limited to the effects of individual risk factors, and we did not assess the risk associated with multiple concurrent factors. Our inclusion criteria led to the selection of studies enrolling a specifically defined population, and results may not be applicable to different populations. Also, we focused on factors that increase risk for breast cancer in collaboration with the development of the CISNET models. Clinical application of our estimates of factors associated with reduced risk is limited because the CISNET models were not designed for similar reduced-risk scenarios.
This comprehensive systematic review and metaanalysis of risk factors for breast cancer in women aged 40 to 49 years, as well as a primary analysis of the same risk factors using BCSC data, indicated that having either extremely dense breast tissue on mammography or firstdegree relatives with breast cancer is associated with at least a 2-fold increased risk for breast cancer. Identification of these risk factors may be useful for personalized mammography screening. Note: Each cancer registry and the Statistical Coordinating Center have received institutional review board approval for either active or passive consenting processes or a waiver of consent to enroll participants, link data, and perform analytic studies. All procedures are compliant with the Health Insurance Portability and Accountability Act, and all registries and the Statistical Coordinating Center have received a federal Certificate of Confidentiality and other protection for the identities of women, physicians, and facilities participating in this research. A list of the BCSC investigators and procedures for requesting BCSC data for research purposes is provided at http://breastscreening.cancer.gov/.
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